Table 2.
Parameters during FMD measurements, BNP, and TRPG at baseline and after bosentan treatment
| PAH | CTEPH | P (PAH vs. CTEPH, unpaired t) | ||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | After bosentan | P (paired t) | Baseline | After bosentan | P (paired t) | Baseline | After bosentan | |
| FMD, % | 6.01 ± 2.42 | 8.07 ± 3.18 | <0.001 | 6.04 ± 1.95 | 6.21 ± 3.15 | 0.910 | 0.98 | 0.193 |
| Heart rate, bpm | 82.2 ± 14.8 | 81.3 ± 15.8 | 0.884 | 81.3 ± 15.8 | 72.8 ± 10.9 | 0.111 | 0.88 | 0.134 |
| Systolic BP, mmHg | 108.3 ± 19.4 | 109.4 ± 19.7 | 0.831 | 124.6 ± 12.2 | 131.1 ± 22.3 | 0.562 | 0.017 | 0.035 |
| Diastolic BP, mmHg | 72.2 ± 14.0 | 69.3 ± 9.6 | 0.634 | 82.6 ± 8.4 | 74.6 ± 7.4 | 0.057 | 0.031 | 0.138 |
| BNP, pg/mL | 344 ± 354 | 249 ± 315 | 0.046 | 115 ± 109 | 116 ± 141 | 0.976 | 0.021 | 0.150 |
| TRPG, mmHg | 77.7 ± 25.5 | 68.4 ± 23.5 | 0.123 | 74.9 ± 23.7 | 67.3 ± 26.8 | 0.332 | 0.794 | 0.922 |
Note
Data are mean ± SD. BNP: brain natriuretic peptide; BP: blood pressure; CTEPH: chronic thromboembolic pulmonary hypertension; FMD: flow-mediated vasodilation; PAH: pulmonary arterial hypertension; TRPG: tricuspid regurgitation peak gradient.